ArticleJournal of clinical hypertension (Greenwich, Conn.)2026
The Effect Modification of Systolic Blood Pressure on the Association of Frailty and Cardiovascular Disease in Community-Dwelling Adults.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Limitations in Blood Pressure and Frailty Categorization.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Frailty has been increasingly recognized as an important predictor of cardiovascular disease (CVD) risk; however, the modifying role of systolic blood pressure (SBP) in this association remains unclear. Using data from the China Health and Retirement Longitudinal Study, we included 7210 community-dwelling adults aged ≥45 years and assessed frailty status using a constructed frailty index. Participants were stratified according to SBP levels, and incident CVD events were ascertained during follow-up. Cox proportional hazards models were applied to evaluate the association between frailty and CVD risk, with SBP examined as an effect modifier. Over 53 531 person-years of follow-up, 1663 CVD events occurred. Frailty was consistently associated with a higher risk of CVD across all SBP strata. Each standard deviation increase in the frailty index was associated with a 28% higher CVD risk among participants with SBP <120 mmHg, a 54% higher risk among those with SBP 120-129 mmHg, and a 25% higher risk among those with SBP ≥130 mmHg. Joint analysis demonstrated that frail individuals with SBP 120-129 mmHg had the highest CVD risk (hazard ratio 3.40; 95% confidence interval 2.54-4.57). Sensitivity analyses confirmed a robust interaction between SBP and frailty in relation to CVD risk. These findings indicate that frailty substantially increases CVD risk across all SBP categories, with the greatest risk observed in frail individuals with high-normal SBP, suggesting that individualized blood pressure targets incorporating frailty status may optimize cardiovascular prevention rather than uniformly pursuing lower SBP levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.